ArticleBiomedical reports2021
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.
Article in Biomedical reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Gastro-Oesophageal Reflux Disease Outcomes Following Roux-en-Y Gastric Bypass Surgery in Patients with Obesity: A Systematic Review and Meta-analysis.Obesity surgery · 2025Pooled it
- A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.Journal of gastroenterology and hepatology · 2022Pooled it
- Real-World Observational Clinical Study Assessing the Effectiveness and Safety of Vonoprazan-Based Dual Therapy Versus Proton Pump Inhibitor-Based Triple Therapy forGastroenterology research · 2026Article
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Review
- Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates.CPT: pharmacometrics & systems pharmacology · 2025Article
- Current Management and Treatment Paradigms of Gastroesophageal Reflux Disease following Sleeve Gastrectomy.Journal of clinical medicine · 2024Review
- [Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders].The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Gastroesophageal Reflux Disease in Obesity: Bariatric Surgery as Both the Cause and the Cure in the Morbidly Obese Population.Journal of clinical medicine · 2023Review
- New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2023Article
- Progress on the Mechanism of Visceral Hypersensitivity in Nonerosive Reflux Disease.Gastroenterology research and practice · 2022Review
- Refractory Gastroesophageal Reflux Disease: A Management Update.Frontiers in medicine · 2021Review
- [Impact of P-CABs in the Treatment of Acid-related Diseases: an Evidence Review].Acta gastroenterologica LatinoamericanaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vonoprazan, a novel potassium-competitive acid blocker, results in greater inhibition of gastric acid secretion than proton pump inhibitors (PPI). The aim of this study was to assess the long-term outcomes of patients with PPI-resistant gastroesophageal reflux disease (GERD) treated with vonoprazan. The medical records of patients with symptomatic GERD treated with vonoprazan for 1 year were retrospectively reviewed. Changes in abdominal symptoms were assessed using the Izumo scale, a self-reported questionnaire which is useful in evaluating the symptoms of GERD, epigastric pain, postprandial distress, constipation and diarrhea, and is commonly used in routine clinical practice. A total of 30 patients were included and stratified into a non-erosive (n=22) and erosive group (n=8). At baseline, postprandial distress symptoms were significantly greater in the non-erosive group compared with the erosive group (P=0.013). Even with vonoprazan therapy, symptoms of GERD in the non-erosive group were refractory compared with the erosive group, and required additional treatment in a larger proportion of patients (45 vs. 13%). GERD symptoms in the non-erosive group significantly improved from baseline and remained better after 1 year of vonoprazan therapy, similar to the erosive group. In addition, vonoprazan improved epigastric pain and postprandial distress symptoms in the non-erosive group, and 1 year of vonoprazan therapy did not aggravate constipation or diarrhea. In conclusion, 1 year of vonoprazan therapy improves GERD symptoms in patients with PPI-resistant GERD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.